Company / Capital Returned to Shareholders
Amgen Capital Returned to Shareholders History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$5.1B
FY2025
5-year range
$4.6B / $10.6B
FY2021-FY2025
Trend
+1.8%
vs FY2024
Sector context
#6 of 52
Health Care
What the data says
Amgen's capital returned to shareholders of $5.1B is higher than 88% of companies in the Health Care sector (FY2025). Capital Returned to Shareholders has fluctuated over the past 10 years, ranging from $4.6B in FY2023 to $21.3B in FY2018.
Based on SEC 10-K filings.
$5.1B in FY2025 with a 5-year CAGR of -6.7%. Top quartile in the Health Care sector.
Improved from $4.6B to $5.1B over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -21.4%
- 5-Year CAGR
- -6.7%
- 10-Year CAGR
- -
Sector benchmark
+277.1% above sector average
Key checks
Key Insights
- 5-year CAGR of -6.7%, indicating a declining trend.
- In FY2025, capital returned to shareholders increased 1.8% year-over-year.
- Ranks #6 out of 52 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.1B | +1.8% |
| FY2024 | $5.0B | +10.4% |
| FY2023 | $4.6B | -56.8% |
| FY2022 | $10.6B | +17.4% |
| FY2021 | $9.0B | +24.1% |
| FY2020 | $7.2B | -35.4% |
| FY2019 | $11.2B | -47.4% |
| FY2018 | $21.3B | +226.5% |
| FY2017 | $6.5B | +9.4% |
| FY2016 | $6.0B | +39.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026